Results 121 to 130 of about 6,454 (219)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide

Cardiovascular Diabetology
Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the clinical outcomes of patients with type 2 diabetes.
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, Ada Pesapane, Manuela Giovanna Basilicata, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Maria Teresa Vietri, Annalisa Capuano, Giuseppe Paolisso, Michelangela Barbieri   +12 more
doaj   +1 more source

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review [PDF]

Introduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus ...
Haj Obeid, Esmail, Jentkiewicz, Aleksander, Kalinowska, Alicja, Kozieł, Adrian, Krasowski, Michał, Krupa, Jan, Kurek, Zofia, Malinowski, Maciej, Pietras, Wiktoria, Ulrych, Jakub   +9 more
core   +1 more source

Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs

Advanced Healthcare Materials, Volume 15, Issue 5, 2 February 2026.
Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner, Stefan Keim, Soheil Haddadzadegan, Odile Fernandez Romero, Katrin Zöller, Gabriel Stern, Ilaria Cesi, Krum Kafedjiiski, Andreas Bernkop‐Schnürch   +8 more
wiley   +1 more source

Tirzepatide-induced ketoacidosis in non-diabetic patients

European Journal of Case Reports in Internal Medicine
Background: Tirzepatide is a novel glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonist. It was recently approved for diabetes control and weight reduction in non-diabetic patients. Case description: We report the
Pathan Mohamad Rafe Iqbal, Ossama Sajeh Maadarani, Zouheir Ibrahim Bitar   +2 more
doaj   +1 more source

GLP‐1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study

BJUI Compass, Volume 7, Issue 2, February 2026.
Abstract Objectives The purpose of this study is to investigate the impact of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) use on 90‐day postoperative outcomes and overall survival following partial nephrectomy (PN) for renal cell carcinoma (RCC), where type 2 diabetes mellitus (T2DM) is a common comorbidity.
Sam Kwon, Fiona Wardrop, Diego Gonzalez, Francis Ryan, Liza Khutsishvili, Rollins Turner, Mohammad Ghassab Deameh, Michael J. Whalen   +7 more
wiley   +1 more source

When new therapies meet old challenges: tirzepatide–warfarin interaction in a mechanical mitral valve patient

European Journal of Case Reports in Internal Medicine
Tirzepatide is a medication capable of controlling blood glucose levels through the dual agonism of GIP and GLP-1 receptors. In particular, GLP-1 reduces food intake and delays gastric emptying. We report the case of a 66-year-old woman hospitalised with
Raffaele Natale, Annadora Morena, Luca Maria Capece, Sofia Donnarumma, Ermenegilda Pagano, Fabrizio Pasanisi, Lidia Santarpia   +6 more
doaj   +1 more source

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers ...
Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J. S. Coats, Dike Ojji, Adriana Puente Barragán, Peter Rossing, Shelley Zieroth, Shaaf Ahmad, Shariq Usman, Geeta Appannah, Alison L. Bailey, Ahmed Bennis, Andrea Brandao, Javed Butler, Melanie J. Davies, Lubomira Fabryova, Yuan‐Lin Guo, Hidetaka Itoh, Uday M. Jadhav, Carel W. Le Roux, Fausto J. Pinto, Julio Rosenstock, Banshi Saboo, Hani Sabbour, Mangesh Tiwaskar, Karol E. Watson, Kwang Wei Tham, Fernando Stuardo Wyss, Walter P. Abhayaratna, William T. Abraham, Wael Al Mahmeed, Alessia Argirò, John J. Atherton, Danielle Belardo, Raquel Campuzano, Nandini Chatterjee, Marc‐André Cornier, Sarah Davies, Clemencia de Rueda Panadero, Anastase Dzudie, Ty J. Gluckman, Muhammad Shahzeb Khan, Kamlesh Khunti, Yuri Lopatin, Zhiyi Ma, Okechukwu S. Ogah, Abraham Oomman, Emilio S. Peralta Lopez, Ping Li, Paul Poirier, Julie Redfern, Giuseppe M. C. Rosano, Donna Ryan, Amit Saraf, Sameh Shaheen, Subodh Verma, Stephan von Haehling, Martha Gulati, Naveed Sattar, Jose Luis Zamorano   +60 more
wiley   +1 more source

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes [PDF]

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024.
Almandoz, J, Anderson, L, Barnard-Kelly, K, Battelino, T, Blüher, M, Busetto, L, Catrinou, D, Ceriello, A, Cos, X, Danne, T, Dayan, CM, Del Prato, S, Fernández-Fernández, B, Fioretto, P, Forst, T, Gavin, JR, Giorgino, F, Groop, PH, Harsch, IA, Heerspink, HJL, Heinemann, L, Ibrahim, M, Jadoul, M, Jarvis, S, Ji, L, Kanumilli, N, Kosiborod, M, Landmesser, U, Macieira, S, Mankovsky, B, Marx, N, Mathieu, C, McGowan, B, Milenkovic, T, Moser, O, Müller-Wieland, D, Papanas, N, Patel, DC, Pfeiffer, AFH, Rahelić, D, Rodbard, HW, Rydén, L, Schaeffner, E, Schnell, O, Spearman, CW, Standl, E, Stirban, A, Tacke, F, Topsever, P, Van Gaal, L   +49 more
core  

Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE‐Based Network Meta‐Analysis

Obesity, Volume 34, Issue 2, Page 279-293, February 2026.
ABSTRACT Objective This review compared antiobesity strategies—obesity management medications (OMM), endoscopic bariatric procedures (EBP), and metabolic bariatric surgery (MBS)—with lifestyle intervention, placebo, or no therapy (LSI/Pbo/NT). Methods This network meta‐analysis included randomized clinical trials comparing OMM, EBP, and MBS versus LSI ...
Maurizio De Luca, Ricardo V. Cohen, Amanda Belluzzi, Giuseppe Navarra, Nicola Di Lorenzo, Tarissa B. Z. Petry, Paolo Sbraccia, Luca Busetto, Silvio Buscemi, Rocco Barazzoni, Benedetta Ragghianti, Edoardo Mannucci, Matteo Monami   +12 more
wiley   +1 more source

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2437-2442, March 2026.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source